Epileptic Disorders
MENUClassification is not EZ (Invited Editorial Comment) Volume 7, numéro 4, December 2005
Auteur(s) : Jerome Engel, Jr.
Departments of Neurology and Neurobiology and the Brain Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, U.S.A.
The 1981 International Classification of Epileptic Seizures and the 1989 International Classification of Epilepsies and Epileptic Syndromes have been widely accepted, resulting in an unprecedented standardization of terminology used by the international epilepsy community. These classifications however, are imperfect and have been rightly criticized for a variety of reasons, from the time they were proposed. Since 1997, a Task Force of the International League against Epilepsy (ILAE) has been charged with evaluating the current classifications and recommending changes. Several reports of this Task Force have been published (Engel 1998, Engel 2001, Blume et al. 2001), including a proposal for a diagnostic scheme to be used when describing individual patients (Engel 2001), but no new classification has yet been proposed. A Core Group of the ILAE Task Force (table 1) is currently hard at work finalizing a report that will suggest the use of a rigorous, evidence-based approach to identifying epileptic seizure types and epilepsy syndromes as discrete diagnostic entities, as well as plans for organizing these diagnostic entities into categories or classifications that will be useful for various purposes.
Table 1. ILAE Task force on classification and terminology core group
Jerome Engel, Jr. (Chair) – Los Angeles, CA, USA |
Frederick Andermann – Montreal, Quebec, Canada |
Giuliano Avanzini – Milan, Italy |
Anne Berg – DeKalb, IL, USA |
Samuel Berkovic – Melbourne, Australia |
Warren Blume – London, Ontario, Canada |
Olivier Dulac – Paris, France |
Natalio Fejerman – Buenos Aires, Argentina |
Hans Lüders – Cleveland, OH, USA |
Masakazu Seino – Shizuoka, Japan |
Peter Williamson – Lebanon, NH, USA |
Peter Wolf – Dianalund and Copenhagen, Denmark |
In this issue of Epileptic Disorders, Loddenkemper et al., from the Cleveland Clinic, have proposed an alternative diagnostic scheme which they refer to as a "classification."
Dr. Hans Lüders, who is senior author of this proposal and a member of the ILAE Task Force Core Group, has been a strong critic of the 1981 and 1989 classifications, and has made important conceptual contributions to the work of the ILAE Task Force. There remains however, a major fundamental difference between the approach to epilepsy classification used at the Cleveland Clinic and that used by the mainstream of the international epilepsy community and supported by the ILAE. A principal component of the standard approach to epilepsy classification is the identification of epilepsy syndromes with specific diagnostic, therapeutic, and prognostic implications. A valid criticism of this approach is the fact that a syndromic diagnosis cannot be made in many patients with epilepsy, although the percentage of patients for whom a syndromic diagnosis is not possible has varied considerably from one study to another, due largely to methodological differences (Manford et al. 1992, Berg et al. 1999, Freitag et al. 2001, Kellinghaus et al. 2004). Clearly, syndromic diagnoses are most useful in pediatric epileptology, particularly for children with idiopathic epilepsies, but are of dubious value for many patients with focal symptomatic epilepsies. In addition, it is often difficult to make syndromic diagnoses in patients at the time they appear with new onset epilepsy.
The basic premise of the Cleveland Clinic diagnostic approach has been that emphasis should be placed on a detailed description of the ictal event, and proponents have argued that a syndromic diagnosis is actually unnecessary (Onsurbe et al. 1999). Criticisms of this approach include the fact that it is not a classification, but rather, a means to describe clinical characteristics of individual patients, and that detailed descriptions of ictal events usually do not provide sufficient information for determining the diagnostic work-up, treatment, and prognosis, nor are detailed seizure descriptions possible in many patients who are not admitted for video EEG monitoring. The Cleveland Clinic "classification" is particularly useful however, for patients with focal symptomatic epilepsy who are candidates for localized surgical resection.
The ILAE Task Force has taken a different approach
to addressing the shortcomings of syndromic diagnoses. This
approach maintains that the diagnosis of a specific syndrome, when
possible, is highly desirable because it immediately communicates
considerable information about the patient, with respect to the
diagnostic evaluation required, appropriate treatments, and
prognosis. The Task Force recognizes however, that many patients
have epilepsy conditions that do not fit clearly into well defined
syndromes, and recommends that, for these patients, further
evaluation, treatment, and prognosis should be based on diagnosis
of a specific seizure type (Engel 2001). These ictal diagnostic
entities are currently being defined, based on presumed
pathophysiological and anatomical substrates, as an adjunct to
syndromic diagnosis, as opposed to the purely descriptive ictal
phenomenology recommended in the Cleveland Clinic approach.
Consequently, when a syndromic diagnosis cannot be made, either
because it is too early in the course of the disorder, or the
symptom complex is not consistent with an accepted syndrome,
diagnostic evaluation, therapy, and prognosis would follow from
diagnosis of the seizure type(s). Seizure types as diagnostic
entities, rather than descriptive phenomenology therefore, are a
new and important feature of the diagnostic scheme proposed by the
ILAE (Engel 2001). Seizure-type diagnoses are intended to
supplement syndromic diagnoses, or substitute for syndromic
diagnoses when these are not possible.
Detailed descriptions of ictal phenomenology, as recommended by
Dr. Lüders and his colleagues for classifying epilepsy, do not
per se carry diagnostic, therapeutic, or prognostic
implications. Nor can they be easily organized into categories to
constitute a useful classification for clinical or basic research
purposes, but rather, constitute a unique description for each
individual patient. Perhaps for this reason, the Cleveland Clinic
group now appears to have softened their opposition to syndromic
diagnoses by including them when they exist, in Dimension 1 of
their diagnostic scheme. Although they maintain that localization
of the epileptogenic zone (EZ), the principal element of
Dimension 1, is the most important part of the diagnostic
information in their scheme, clearly this is greatly modified by
the syndromic diagnosis, except in patients with focal symptomatic
epilepsies. For instance, identifying the entire brain as the EZ
would carry no important information for distinguishing a patient
with Lennox-Gastaut syndrome from one with childhood absence
epilepsy, whereas inclusion of the syndromic diagnosis does this.
Conversely, once the syndrome is identified, what is the point of
localizing the EZ? Localization of the EZ is of great importance in
patients with focal symptomatic epilepsy who are candidates for
surgical therapy, but what diagnostic, therapeutic, or prognostic
value does it have beyond this? Dimension 2 is not a seizure
classification, but merely a detailed description of ictal
phenomenology. These descriptions do not have the diagnostic,
therapeutic, or prognostic implications of the seizure types
proposed in the ILAE diagnostic scheme (Engel 2001). A detailed
description of ictal phenomena can be useful for determining the
location of the EZ in patients who are surgical candidates, but
does not add anything to a syndromic or seizure diagnosis, and can
be misleading. For instance, ictal semiology of a focal seizure due
to benign childhood epilepsy with centrotemporal spikes can be
identical to the ictal semiology due to a focal structural lesion
in the rolandic area.
The concept of classification has been openly debated by members
of the ILAE Task Force Core Group (Wolf 2003, Engel 2003, Lüders
et al. 2003, Berg et al. 2003, Avanzini et al.
2003). Classifications are generally used to recognize and
categorize natural classes that can be reproducibly distinguished
from all other natural classes (Ax 1996), as in biological
taxonomy. In the case of epilepsy classification, the challenge is
to identify specific diagnostic entities that can be reproducibly
distinguished from all other diagnostic entities. The ILAE Task
Force Core Group is making a considerable effort to establish
evidence-based criteria for recognizing specific seizure types and
syndromes as unique diagnostic entities equivalent to natural
classes. Further categorization or classification of these
diagnostic entities provides a framework not only for describing
individual patients or for teaching, but for organizing patients
into relatively homogeneous groupings for epidemiological studies;
investigations into basic mechanisms that could eventually lead to
novel therapies and prevention; identification of specific
etiologies, including genetics; and other research purposes. In
this sense, the proposal of Loddenkemper et al. is not a
classification, but merely a diagnostic scheme similar to the one
previously proposed by the ILAE (Engel 2001). For this reason, it
becomes necessary to ask whether this new diagnostic scheme
includes anything that is not already in the ILAE diagnostic
scheme.
Table 2 compares the five dimensions of
the Cleveland Clinic, patient-oriented, epilepsy classification
proposed by Loddenkemper et al., with the five axes of the
ILAE diagnostic scheme (Engel 2001).
Table 2. Comparison of the Cleveland Clinic and ILAE diagnostic schemes
Cleveland Clinic |
ILAE | ||
Dimension 1 |
Epilepsy localization1 Seizure semiology2 Etiology3 Seizure frequency4 Related medical condition If applicable6 |
Axis 1 Axis 2 Axis 3 Axis 4 Axis 5 |
Ictal phenomenology Seizure type5 Syndrome Etiology Impairment6 |
1 Localization is included in Axis 4;
this Dimension also includes syndrome (Axis 3)
2 This is the same as Axis 1 although a detailed
description is not mandatory in Axis 1
3 This is the same as Axis 4
4 Seizure frequency is included in Axis 1
5 This is a unique concept not included in the
Cleveland Clinic scheme
6 These two categories are different, but optional
Dimension 1, epilepsy localization, is included as
part of the etiological diagnosis in Axis 4 of the ILAE diagnostic
scheme. The syndrome diagnosis, which is also included where
possible in Dimension 1 of the Cleveland Clinic scheme, is the same
as Axis 3 of the ILAE diagnostic scheme. It is worth noting that
Axis 3 recognizes that a syndromic diagnosis is not always
possible.
Dimension 2 of the Cleveland Clinic scheme is essentially the same
as Axis 1 of the ILAE classification, with minor differences in
terminology (Blume et al. 2001). Unlike Dimension 2 of the
Cleveland Clinic scheme, Axis 1 of the ILAE scheme allows the
clinical situation to determine the degree of descriptive detail.
Axis 1 also includes seizure frequency, which is Dimension 4 of the
Cleveland Clinic scheme. Axis 2 of the ILAE scheme, seizure type as
a diagnostic entity however, does not appear in the Cleveland
Clinic scheme, which is an important omission. Consequently, there
is nothing contained in the first four dimensions of the Cleveland
Clinic scheme that is not also contained in the ILAE scheme, while
the important seizure-type diagnostic entity of the ILAE scheme is
missing from the Cleveland Clinic scheme.
The fifth categories of the two schemes are entirely different;
Dimension 5 of the Cleveland Clinic scheme lists related medical
conditions if applicable, while Axis 5 of the ILAE diagnostic
scheme is an optional assessment of impairment, using a WHO scale.
Although debate is justified as to whether either of these two
categories needs to be included in a formal diagnostic scheme, this
does not reflect a major concern for choosing one approach over the
other, or justify the need for a new diagnostic scheme. The issue,
therefore, is primarily whether a diagnostic scheme which
emphasizes localization of the EZ would accurately define more
patients, provide more clinically useful information, and be more
easily communicated than a scheme which emphasizes seizure types
and syndromes as diagnostic entities. Localization of the EZ is
extremely difficult even in the best of circumstances and can be
achieved only in a small minority of patients in the general
population (Manford et al. 1992), while a seizuretype
diagnosis is usually possible when a syndrome diagnosis is not.
Localization of the EZ in itself provides little or no information
about the diagnostic evaluation required, therapy needed, or, most
importantly, prognosis, whereas diagnosis of a specific seizure
type and syndrome do. Finally, it is not clear how localization of
the EZ, or the Cleveland Clinic diagnostic approach itself, would
be used to easily communicate information among physicians in a
manner comparable to stating that a patient has mesial temporal
lobe epilepsy or typical absence seizures. What we now need of
course, is independent field-testing to compare the clinical
utility of various diagnostic schemes (Kälviäinen et al.
2005).
Personally, and I must speak here for myself and not the ILAE Task
Force, I appreciate the work that the Cleveland Clinic group
continues to do to pursue the possible applications of their
"classification" system, and recognize that it has contributed
importantly to the work of the ILAE Task Force [Axis 1 of the
diagnostic scheme (Blume et al. 2001)]. However, I see no
compelling need for this new diagnostic approach when the scheme
proposed by the ILAE Task Force contains essentially the same
information, as well as the additional important diagnostic entity
of seizure type. Furthermore, the primary emphasis of this new
proposal on the location of the EZ has clinical importance only for
a small minority of patients with focal symptomatic epilepsy who
are candidates for surgery. A variation of the Cleveland Clinic
diagnostic scheme however, might be adapted by the ILAE Task Force,
specifically for patients with focal symptomatic epilepsy.